An Update on Innate Immune Responses during SARS-CoV-2 Infection

Viruses. 2021 Oct 14;13(10):2060. doi: 10.3390/v13102060.

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a member of the Coronaviridae family, which is responsible for the COVID-19 pandemic followed by unprecedented global societal and economic disruptive impact. The innate immune system is the body's first line of defense against invading pathogens and is induced by a variety of cellular receptors that sense viral components. However, various strategies are exploited by SARS-CoV-2 to disrupt the antiviral innate immune responses. Innate immune dysfunction is characterized by the weak generation of type I interferons (IFNs) and the hypersecretion of pro-inflammatory cytokines, leading to mortality and organ injury in patients with COVID-19. This review summarizes the existing understanding of the mutual effects between SARS-CoV-2 and the type I IFN (IFN-α/β) responses, emphasizing the relationship between host innate immune signaling and viral proteases with an insight on tackling potential therapeutic targets.

Keywords: SARS-CoV-2; innate immune response; type I interferons.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Antiviral Agents / therapeutic use
  • COVID-19 / immunology*
  • COVID-19 / pathology
  • COVID-19 Drug Treatment
  • Cytokines / metabolism
  • Drug Combinations
  • Humans
  • Immune Evasion / immunology*
  • Immunity, Innate / immunology*
  • Interferon Type I / biosynthesis
  • Interferon Type I / immunology*
  • Lopinavir / therapeutic use
  • Ribavirin / therapeutic use
  • Ritonavir / therapeutic use
  • SARS-CoV-2 / immunology*
  • Signal Transduction / immunology

Substances

  • Antiviral Agents
  • Cytokines
  • Drug Combinations
  • Interferon Type I
  • lopinavir-ritonavir drug combination
  • Lopinavir
  • Ribavirin
  • Ritonavir